← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. GRFS
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

GRFS logoGrifols, S.A. (GRFS) P/E Ratio History

Historical price-to-earnings valuation from 2011 to 2025

Current P/E
12.1
Undervalued
5Y Avg P/E
22.0
-45% vs avg
PE Percentile
5%
Low
PEG Ratio
N/A
N/A
TTM EPS$0.59
Price$8.06
5Y PE Range11.3 - 42.6
Earnings Yield8.30%

Loading P/E history...

GRFS Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
12.1vs22.0
-45%
Cheap vs History
vs. Healthcare
12.1vs22.3
-46%
Below Sector
vs. S&P 500
12.1vs25.1
-52%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 148% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 8, 2026, Grifols, S.A. (GRFS) trades at a price-to-earnings ratio of 12.1x, with a stock price of $8.06 and trailing twelve-month earnings per share of $0.59.

The current P/E is 45% below its 5-year average of 22.0x. Over the past five years, GRFS's P/E has ranged from a low of 11.3x to a high of 42.6x, placing the current valuation at the 5th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.3x, GRFS trades at a 46% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

Relative to the broader market, GRFS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GRFS DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GRFS P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
TAK logoTAKTakeda Pharmaceutical Company Limited
$53B77.64.10-26%
CSL logoCSLCarlisle Companies Incorporated
$15B21.10.87Best-39%
OCSL logoOCSLOaktree Specialty Lending Corporation
$1B31.3--46%
BCRX logoBCRXBioCryst Pharmaceuticals, Inc.
$2B7.4Lowest-+381%Best
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$39B127.0-+207%
BIO logoBIOBio-Rad Laboratories, Inc.
$7B9.2-+143%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

GRFS Historical P/E Data (2011–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$9.35$0.5915.9x-40%
FY2025 Q3$9.96$0.5518.2x-32%
FY2025 Q2Mon Jun 30 2025 00:00:00 GM$9.04$0.4320.8x-22%
FY2025 Q1Mon Mar 31 2025 00:00:00 GM$7.11$0.2825.0x-6%
FY2024 Q4$7.44$0.2332.9x+24%
FY2024 Q3Mon Sep 30 2024 00:00:00 GM$8.88$0.2142.6x+60%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$6.31$0.2228.6x+8%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$6.68$0.4016.7x-37%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$11.56$0.5620.6x-22%
FY2023 Q3Sat Sep 30 2023 00:00:00 GM$9.14$0.8111.3x-57%
FY2021 Q2Wed Jun 30 2021 00:00:00 GM$17.35$1.1415.2x-43%
FY2021 Q1Wed Mar 31 2021 00:00:00 GM$17.29$0.9917.5x-34%

Average P/E for displayed period: 26.6x

See GRFS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is GRFS Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare GRFS vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

GRFS — Frequently Asked Questions

Quick answers to the most common questions about buying GRFS stock.

Is GRFS stock overvalued or undervalued?

GRFS trades at 12.1x P/E, below its 5-year average of 22.0x. At the 5th percentile of historical range, the stock is priced at a discount to its own history.

How does GRFS's valuation compare to peers?

Grifols, S.A. P/E of 12.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.

What is GRFS's PEG ratio?

GRFS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2025.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

GRFS P/E Ratio History (2011–2025)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.